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648Novel Once-Daily Extended-Release Tacrolimus Versus
Twice-Daily Tacrolimus in De Novo Kidney Transplant
Recipients: Two-Year Results of Phase 3, Double-Blind,
Randomized Trial
Lionel Rostaing, MD, PhD,1 Suphamai Bunnapradist, MD,2 Josep M. Grinyo´, MD,3
Kazimierz Ciechanowski, MD, PhD,4 Jason E. Denny, MD,5
Helio Tedesco Silva Jr, MD,6 and Klemens Budde, MD,7 on behalf of the Envarsus
Study Group*
Background: 1-year data from this trial showed the noninferiority of a novel once-daily extended-release
tacrolimus (LCPT;EnvarsusXR) to immediate-release tacrolimus (IR-Tac) twicedailyafter kidney transplantation.
Study Design: Final 24-month analysis of a 2-armed, parallel-group, randomized, double-blind, double-
dummy, multicenter, phase 3 trial.
Setting & Participants: 543 de novo kidney recipients randomly assigned to LCPT (n 5 268) or IR-Tac
(n5 275); 507 (93.4%) completed the 24-month study.
Intervention: LCPT tablets once daily at 0.17 mg/kg/d or IR-Tac twice daily at 0.1 mg/kg/d; subsequent
doses were adjusted to maintain target trough ranges (first 30 days, 6-11 ng/mL; thereafter, 4-11 ng/mL).
The intervention was 24 months; the study was double blinded for the entirety.
Outcomes & Measurements: Treatment failure (death, transplant failure, biopsy-proven acute rejection, or
loss to follow up) within 24 months. Safety end points included adverse events, serious adverse events, new-
onset diabetes, kidney function, opportunistic infections, and malignancies. Pharmacokinetic measures
included total daily dose (TDD) of study drugs and tacrolimus trough levels.
Results: 24-month treatment failure was LCPT, 23.1%; IR-Tac, 27.3% (treatment difference, 24.14% [95%
CI, 211.38% to 13.17%], well below the 110% noninferiority criterion defined for the primary 12-month end
point). Subgroup analyses showed fewer treatment failures for LCPT versus IR-Tac among black, older, and
female recipients. Safety was similar between groups. From month 1, TDD was lower for LCPT; the difference
increased over time. At month 24, mean TDD for LCPT was 24% lower than for the IR-Tac group (P, 0.001),
but troughs were similar (means at 24 months: LCPT, 5.47 6 0.17 ng/mL; IR-Tac, 5.8 6 0.30 ng/mL; P 5 0.4).
Limitations: Trial participant eligibility criteria may limit the generalizability of results to the global population
of de novo kidney transplant recipients.
Conclusions: Results suggest that once-daily LCPT in de novo kidney transplantation has comparable
efficacy and safety profile to that of IR-Tac. Lower TDD reflects LCPT’s improved bioavailability and absorption.
Am J Kidney Dis. 67(4):648-659. ª 2016 The Authors. Published by Elsevier Inc. on behalf of the National
Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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transplant recipient; end-stage renal disease (ESRD); randomized controlled trial (RCT).Tacrolimus is overwhelmingly used as an immu-nosuppressant in kidney transplantation, both
early posttransplantation and as part of long-term
maintenance regimens.1 While highly effective in
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LCPT Versus Immediate-Release Tacrolimus(IR-Tac) twice-daily capsule formulation (Prograf;
Astellas Pharma US, Inc).3 In addition, both the
IR-Tac formulation and another extended-release
once-daily tacrolimus formulation (Advagraf/Asta-
graf XL; Astellas Pharma US, Inc) are associated with
similar peak concentrations4; unwanted tacrolimus-
associated neurologic adverse events (AEs) have
been noted to happen or be most pronounced at peak
serum tacrolimus blood concentrations.5-7 Addition-
ally, the twice-daily formulation adds further pill
burden to a patient population already encumbered
with taking many long-term medications. Multiple
daily drug dosing is associated with increased risk for
nonadherence8-10; this may result in acute rejection11
and, in severe cases, transplant failure.12
The medication LCP-Tacro (LCPT; Envarsus XR;
Veloxis Pharmaceuticals) is an extended-release
tablet formulation of tacrolimus with once-daily
dosing that has been developed using a proprietary
MeltDose drug delivery technology (Veloxis Phar-
maceuticals), distinguishing LCPT from other once-
daily extended-release tacrolimus products (eg,
Astagraf XL). The MeltDose technology decreases a
drug’s particle size to the smallest possible units as
single molecules (ie, a “solid solution”).13 Drug
particle size critically affects drug dissolution and
absorption; if particle size is smaller, the surface area
of the drug increases and the drug will be dissolved
more quickly, resulting in better absorption.14 Re-
sults of the MeltDose technology are increased ab-
sorption and bioavailability associated with LCPT
tablets compared with other extended-release and IR
tacrolimus formulations currently available. Phase 1
and phase 2 trials conﬁrmed that LCPT enables
broader absorption throughout the gastrointestinal
tract and sustains consistent tacrolimus concentra-
tions.15 In addition, LCPT showed a lack of diurnal
variability16 common with other formulations.3,17
Phase 2 trials of de novo and stable kidney18,19
and liver recipients20,21 showed a steadier and
more consistent concentration-time proﬁle over 24
hours, with reduced peak and peak-to-trough ﬂuc-
tuations for LCPT compared to IR-Tac, increased
bioavailability of w30%, and comparable efﬁcacy
and safety proﬁles. A robust correlation between the
area under the curve at 24 hours and the minimum
concentration was also shown, indicating that ther-
apeutic drug monitoring of minimum concentration
as a measure of tacrolimus exposure can be applied
to LCPT. A phase 3 conversion trial showed that
LCPT had noninferior efﬁcacy and comparable
safety proﬁle to IR-Tac, with lower doses (w20%
lower than IR-Tac overall and 30% lower in white
patients) of LCPT.22
Previously, the 12-month primary efﬁcacy and
safety outcomes were reported from this phase 3Am J Kidney Dis. 2016;67(4):648-659double-blind double-dummy trial of de novo kidney
transplant recipients randomly assigned to LCPT or
IR-Tac.23 Here, the prespeciﬁed blinded efﬁcacy and
safety outcomes at 24 months’ follow-up are reported
from this same phase 3 trial. Efﬁcacy was also
analyzed within patient subgroups (ie, females,
blacks, and recipients aged $ 65 years) in order to
explore the consistency of results, or lack thereof,
within speciﬁc patient populations.
METHODS
Study Overview
This was a 2-armed, parallel group, prospective, randomized,
double-blind, double-dummy, multicenter, 24-month, phase 3 trial.
The study design has been previously reported.23 Both the 1- and
the 2-year analyses were a priori planned as explicitly stated in the
study protocol. The primary endpoint was based on the 1-year
analysis and the 2-year analysis was the ﬁnal analysis designed
to assess long-term efﬁcacy and safety outcomes; patients and
investigators stayed blinded for the full 24 months. In brief, adult
de novo recipients of a living or deceased donor kidney transplant
were randomly assigned to receive LCPT tablets once daily on a
starting dose of 0.17 mg/kg/d or IR-Tac twice-daily (Prograf)
capsules at 0.1 mg/kg/d. Subsequent doses of each study drug
were adjusted to maintain whole-blood trough concentrations
within the target range of 6 to 11 ng/mL for the ﬁrst 30 days, then
4 to 11 ng/mL for the rest of the study. All patients also received a
matching double-dummy placebo to maintain the blind. All pa-
tients also received mycophenolate mofetil (1 g twice daily) or
mycophenolic acid (720 mg twice daily), an interleukin 2 receptor
antagonist, and corticosteroids per local practice.
Key study exclusion criteria were as follows: receipt of an organ
transplant other than kidney; panel-reactive antibody. 30%; body
mass index , 18 or .40 kg/m2; receipt of sirolimus, everolimus,
azathioprine, or cyclophosphamide within 3 months before
enrollment; and abnormal laboratory values.
Health authority, ethics committee, and institutional review board
approval were obtained at each participating center, and informed
consent was obtained from all patients. The study was undertaken in
accordance with the ICH (International Conference on Harmo-
nisation of Technical Requirements for Registration of Pharmaceu-
ticals for Human Use) Harmonized Tripartite Guidelines for Good
Clinical Practice and conformed to the Declaration of Helsinki.
Study End Points
Efﬁcacy
The incidence of treatment failures (any of the following: death,
transplant failure, biopsy-proven acute rejection [BPAR; Banff
grade $ 1A, using Banff 2007 criteria; based on centrally read
biopsies], or loss to follow-up) within 24 months after randomi-
zation was compared between LCPT and IR-Tac for the overall
sample and also stratiﬁed by the following subgroups: age (,65
and$65 years), race (black or nonblack), and sex (male or female).
The incidence of each individual event (death, transplant
failure, BPAR, or loss to follow-up) within 24 months after the
randomization date was also assessed. Efﬁcacy results are re-
ported for the overall 24-month study period and separately for
the 0- to 12-month and 13- to 24-month periods.
Safety
Safety end points at 24 months included the following: inci-
dence of AEs, serious AEs (SAEs), and discontinuations due to
AEs; incidence of predeﬁned potentially clinically signiﬁcant
laboratory values; new-onset diabetes after transplantation649
Rostaing et al(NODAT); incidence of posttransplantation lymphoproliferative
disorder; mean change from baseline (day 30) in estimated
glomerular ﬁltration rate (MDRD7 [Modiﬁcation of Diet in Renal
Disease] Study equation); change in clinical laboratory values and
vital signs; incidence of opportunistic infections; and any malig-
nancy or BK virus diseases. As prespeciﬁed in the study protocol,
NODAT analysis was restricted to patients without diabetes at
baseline and patients with no medical history of diabetes, baseline
fasting plasma glucose level , 126 mg/dL, no prior use of a hy-
poglycemic agent for diabetes conditions, no prior use of insulin
for diabetes conditions, or hemoglobin A1c level , 6.5% before
transplantation. Patients meeting the at-risk deﬁnition were
considered to have NODAT if they met any of the following 4
criteria: fasting plasma glucose level $ 126 mg/dL, hemoglobin
A1c level $ 6.5% 90 days or later after randomization, new-onset
oral hypoglycemic agent use, or new-onset insulin use for more
than 30 days. In general, AEs and infections were spontaneously
reported by the investigator and then mapped to MedDRA
(Medical Dictionary for Regulatory Activities) preferred terms.
Statistical Analysis
Sample Size Determination
Sample size determination was based on the 12-month primary
end point. Based on an expected treatment failure rate of 15% at 1
year, 270 patients per group were required to have 90% power to
reject the null hypothesis that LCPT was inferior to IR-Tac based
on a 2-sided 95% conﬁdence interval (CI) upper bound and a 10%
noninferiority margin.
The study design and vigorous 10% noninferiority margin used
for the 12-month analysis were decided upon in pretrial collabo-
ration with the US Food and Drug Administration. Subgroup an-
alyses were prespeciﬁed in the Statistical Analysis Plan for the
study for the 12-month outcomes; the same subgroup analyses
were performed at 24 months for consistency check of the 12- and
24-month data.
Analysis Method
The total daily dose (TDD) the day before a trough sample
recorded in the case report forms was used to compute the ratioPaents Enrol
N=601 
Paents Random
N=543 (ITT)
LCPT 
N=268 
Received ≥1 Dose of Study 
Drug, N=266 
Completed 24 Month Study 
Drug Treatment N=195 
Reasons for early 
disconnuaon: gra failure 
(n=3); AE (n=31); 
unsasfactory therapeuc 
eﬀect (n=1); paent 
voluntarily disconnued 
(n=25); physician decision 
(n=4); non-compliance 
(n=2); other (n=5) 
Completed 24 Month Study Period 
N=253 
Reasons for early disconnuaon: 
death (n=11); AE (n=1); paent 
voluntarily disconnued (n=3)  
Figure 1. Patient disposition. Abbreviations: AE, adverse
650of trough value to dose for each trough sample for each patient. The
ratio was then tabulated by treatment group and time point; dif-
ferences in ratios between groups at each time point were evaluated
by 1-way analysis of variance with main effect of treatment.
Treatment failure within 24 months was assessed using a 2-
sided 95% CI for the difference (LCPT minus IR-Tac) in treat-
ment failure rates between treatment groups. The incidence of
clinically suspected and treated acute rejection episodes and the
incidence of BPAR episodes was compared between treatment
groups using Fisher exact test and 2-sided 95% CI for the differ-
ence. The 2-sided 95% CIs for the differences were calculated
using the Newcombe-Wilson score method. In addition, the as-
sociation between treatment and severity grade of the ﬁrst BPAR
episode was assessed using Cochran-Mantel-Haenszel test for
general association.
Differences between treatment groups in time-to-event distri-
butions were evaluated using log-rank tests, displayed as Kaplan-
Meier curves. Baseline characteristics and treatment-emergent AEs
were tabulated by treatment. Change from baseline in lipid levels
was compared using an analysis of covariance model with main
effect of treatment and baseline as covariates.
RESULTS
Study Overview
The study was initiated on October 13, 2010.
All randomly assigned participants completed the
24-month visit by March 26, 2014, at 68 sites (United
States, n 5 31; Latin America, n 5 13; Europe,
n 5 15; and Asia Paciﬁc, n 5 9).
Patient Disposition and Baseline Characteristics
A total of 543 patients were randomly assigned to
the study drug (intention-to-treat population; LCPT,
n 5 268; IR-Tac, n5 275). Overall, 507 (93.4%)
patients completed the 24-month study period and
394 (72.6%) completed the 24-month study on study
drug (LCPT, n 5 195; IR-Tac, n 5 199; Fig 1).led 
Paents Not Randomized 
N=58 
ized 
 
Tacrolimus Twice-daily 
N=275 
Received ≥1 Dose of Study 
Drug, N=271 
Completed 24 Month Study Period 
N=254 
Reasons for early disconnuaon: 
death (n=13); AE (n=2); lost-to-
follow-up (n=3); paent voluntarily 
disconnued (n=3) 
Completed 24 Month Study 
Drug Treatment N=199 
Reasons for early 
disconnuaon: gra failure 
(n=3); rejecon (n=1); AE 
(n=35); unsasfactory 
therapeuc eﬀect (n=2); 
paent voluntarily 
disconnued (n=23); 
physician decision (n=4); 
other (n=4) 
event; LCPT, extended-release tacrolimus, once daily.
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LCPT Versus Immediate-Release TacrolimusDemographic characteristics were similar between
treatment groups. The patient population was pre-
dominately white (76.8%) and male (65.4%); mean
age was 45.8 years (Table 1).
Immunosuppression
As a result of the higher starting dose for LCPT,
initial TDDs were higher in patients in the LCPT group
versus the IR-Tac group. From months 1 through 12,
TDDs were lower in the LCPT group, and the differ-
ence between groups increased over time. At month 3,
TDD for the LCPT group was w14% lower, and by
month 12,w20% lower. At month 24, mean TDD for
the LCPT group was 24.4% lower than that for the IR-
Tac group (3.46 0.15 [standard error] and
4.56 0.22 mg, respectively; P , 0.001; Fig 2).
Tacrolimus trough levels were notably higher in the
LCPT group compared with the IR-Tac group in the
ﬁrst 2 weeks after dosing; thereafter, trough levels in
the 2 groups were similar (Fig 2). Although a greater
proportion of LCPT (67%) versus IR-Tac (25%) pa-
tients had tacrolimus trough levels $ 6 ng/mL by
day 2,23 the majority of patients in both treatment
groups were within the post–30-day target range of 4
to 11 ng/mL from month 1.5 through month 24
(71.5%-84.5% for LCPT and 78.3%-87.0% for IR-Tac).Table 1. Patient Demographics and Baseline Characteristics
LCPT
(n 5 268)
IR-Tac
(n 5 275)
Age, y 44.8 6 13.29 46.9 6 14.26
Sex
Male 174 (64.9) 181 (65.8)
Female 94 (35.1) 94 (34.2)
Race
White 203 (75.7) 214 (77.8)
Black 10 (3.7) 15 (5.5)
Asian 10 (3.7) 10 (3.6)
Other 45 (16.8) 36 (13.1)
Previous transplant 11 (4.1) 11 (4.0)
Donor type
Living 135 (50.4) 129 (46.9)
Deceased 133 (49.6) 145 (52.7)
Missing 0 (0.0) 1 (0.4)
PRA, % 1.5 6 5.10 1.56 5.98
PRA, 5% 243 (90.7) 253 (92.0)
Diabetes at time of transplantation 50 (18.7) 56 (20.4)
Time from transplantation to
first study drug dose, h
34.156 8.9 34.386 9.7
Note: Values for categorical variables are given as number
(percentage); for continuous variables, as mean 6 standard
deviation.
Abbreviations and definitions: IR-Tac, immediate-release
tacrolimus, twice-daily; LCPT, extended-release tacrolimus,
once daily; PRA, panel-reactive antibody.
Am J Kidney Dis. 2016;67(4):648-659Analysis of trough to dose ratio demonstrated an
increasing ratio for LCPT throughout the 24 months
(Fig 3); this reﬂected the improved absorption pro-
vided by the MeltDose formulation. This is apparent
over time as the dose decreases but the trough level
remains stable and similar to that of IR-Tac. Absorp-
tion (ie, bioavailability) per milligram was signiﬁ-
cantly higher in the LCPT group versus the IR-Tac
group by month 12 (means for LCPT and IR-Tac of
2.36 0.11 and 1.66 0.07, respectively; P , 0.001)
and month 24 (means for LCPT and IR-Tac of
2.26 0.11 and 1.686 0.07, respectively; P , 0.001).
Efﬁcacy End Point
Treatment failure at 24 months was 23.1% for pa-
tients in the LCPT group and 27.3% for patients in the
IR-Tac group. The treatment difference was 24.14%
(95% CI, 211.38% to 13.17%), well below the non-
inferiority margin of 10% that was used for the
12-month primary efﬁcacy end point. No statistically
signiﬁcant difference was observed between the
LCPT and IR-Tac groups for the incidence of all-cause
mortality (P 5 0.8), transplant failure (P5 0.5),
BPAR (P5 0.8), or loss to follow-up (P5 0.4;
Table 2).
No statistically signiﬁcant difference was observed
between the 2 treatment groups in time-to-event dis-
tribution during the 24-month study period by log-rank
test: treatment failure (P 5 0.3) and ﬁrst episode of
BPAR (P 5 0.7). Overall patient survival was 95.9%
versus 95.2% (P 5 0.7), and transplant survival was
95.8% versus 94.4% (P 5 0.4) for LCPT and IR-Tac,
respectively. Both drug groups had more treatment
failures in the ﬁrst versus second 12 months of the
study. In both study years, LCPT had fewer treatment
failures; a larger difference between groups was seen
between study years 1 and 2 compared to the ﬁrst 12
months (Table 2; Fig 4).
There were no statistically signiﬁcant differences
between the 2 treatment groups in incidence of patients
with clinically suspected and treated rejections, num-
ber of BPAR episodes, or severity of the ﬁrst BPAR
episode (Table 3). There were more acute rejection
episodes in the ﬁrst year compared to the second study
year in both groups (Tables 2 and 3).
Subgroup analyses showed that the LCPT group
had fewer treatment failures compared to the IR-Tac
group in females, blacks, and recipients 65 years or
older (Fig 5).
Safety
Treatment-Emergent AEs
Mean numbers of AEs per patient during the study
were 14.3 and 14.4 for the LCPT and IR-Tac groups,
respectively. The incidence of AEs was similar be-
tween the 2 treatment groups (Table 4). AEs reported651
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Rostaing et alin the second year tended to follow the same pattern
as in the ﬁrst study year; however, AEs tended to be
fewer for the second year of the study compared to
the ﬁrst 12 months (percentages of patients with $1
AE in the ﬁrst vs second year were 98% vs 74% and
99% vs 70% for the LCPT and IR-Tac groups,
respectively).
The majority of patients had at least 1 mild (LCPT,
92.2%; IR-Tac, 93.8%) or moderate (LCPT, 82.8%;
IR-Tac, 84.7%) AE. Eighty (29.9%) patients in the
LCPT group and 95 (34.5%) in the IR-Tac group had
at least 1 severe event.
The majority of events (.80%) were not suspected
to be related to study drug. However, 64.9% of0
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652patients in the LCPT group and 59.3% of patients in
the IR-Tac group had at least 1 event suspected to be
related to the study drug.
The proportion of patients who had AEs resulting
in discontinuation from study drug and/or withdrawal
from the study was similar in the treatment groups
(0-12 months: 8.6% in LCPT, 9.8% in IR-Tac; 0-24
months: 11.6% in LCPT, 12.7% in IR-Tac).
Treatment-Emergent SAEs
In the LCPT and IR-Tac groups, 61.9% and 67.3%
of patients, respectively, had treatment-emergent
SAEs. The frequency of SAEs tended to be fewer for
the second year versus the ﬁrst 12 months (percentages450 540 630 720
andomizaon
LCPT Tacrolimus twice-daily
L) achieved per total daily dose (TDD; mg). Abbreviation: LCPT,
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Table 2. Efficacy Results During the First and Second 12 Months and Over the 24-Month Study Period
LCPT (n 5 268) IR-Tac (n 5 275) Treatment Difference (95% CI)a
Treatment failure
0-12 mo 49 (18.3) 54 (19.6) 21.35% (27.94% to 5.27%)
13-24 mob 13 (5.1) 21 (8.0) 22.94% (27.38% to 1.42%)
0-24 mo 62 (23.1) 75 (27.3) 24.14% (211.38% to 3.17%)
Death
0-12 mo 8 (3.0) 8 (2.9) 0.08% (23.02% to 3.21%)
13-24 mob 3 (1.2) 5 (1.9) 20.74% (23.33% to 1.73%)
0-24 mo 11 (4.1) 13 (4.7) 20.62% (24.29% to 3.03%)
Transplant failure
0-12 mo 9 (3.4) 11 (4.0) 20.64% (24.05% to 2.75%)
13-24 mob 2 (0.78) 4 (1.5) 20.75% (23.15% to 1.48%)
0-24 mo 11 (4.1) 15 (5.5) 21.35% (25.15% to 2.40%)
Loss to follow-up
0-12 mo 4 (1.5) 5 (1.8) 20.33% (22.86% to 2.18%)
13-24 mob 0 (0.0) 3 (1.2) NA
0-24 mo 4 (1.5) 8 (2.9) 21.42% (24.29% to 1.27%)
BPAR
0-12 mo 35 (13.1) 37 (13.5) 20.39% (26.14% to 5.38%)
13-24 mob 11 (4.3) 13 (5.0) 20.66% (24.50% to 3.16%)
0-24 mo 46 (17.2) 50 (18.2) 21.02% (27.44% to 5.43%)
Note: Unless otherwise indicated, values are given as number (percentage). The prespecified noninferiority margin was 10%.
Abbreviations: BPAR, biopsy-proven acute rejection; CI, confidence interval; IR-Tac, immediate-release tacrolimus, twice-daily;
LCPT, extended-release tacrolimus, once daily; NA, not applicable.
aTwo-sided 95% CIs were calculated using Newcombe-Wilson score intervals. For the primary efficacy end point (12-month
treatment failure rate), difference between groups was assessed by a noninferiority approach with a noninferiority margin of 10%.
bPercentage was calculated based on persons who participated in the study during this period.
LCPT Versus Immediate-Release Tacrolimusof patients with $1 SAE in the ﬁrst vs second year
were 53% vs 24% and 58% vs 24%, for LCPT and
IR-Tac, respectively).
Twenty-four deaths (11 in LCPT [ﬁrst year, 8;
second year, 3] and 13 in IR-Tac [ﬁrst year, 8; second
year, 5]) occurred during the study. Most causes of
death were related to the cardiopulmonary system.
None of the 11 fatal SAEs in the LCPT group were
suspected to be related to the study drug. Three of theFigure 4. Kaplan-Meier analysis, proportion free of treatment failu
limus, once daily.
Am J Kidney Dis. 2016;67(4):648-65913 patients who died in the IR-Tac group had events
(sepsis) considered to be related to study drug.
Potentially Clinically Signiﬁcant Laboratory Values and
Kidney Function
No statistically signiﬁcant difference was observed
between treatment groups in the incidence of pre-
deﬁned potentially clinically signiﬁcant laboratory
measurements.re over 24 months. Abbreviation: LCPT, extended-release tacro-
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Table 3. Incidence of Clinically Suspected and Treated Acute Rejection Episodes Within 24 Months After Randomization and Severity
of First BPAR Episode
Parameter LCPT (n 5 268) IR-Tac (n 5 275) LCPT – IR-Tac (95% CI)a P
Patients with $1 rejection event
0-12 mo 37 (13.8) 43 (15.6) 21.83% (27.81% to 4.18%) 0.6b
0-24 mo 46 (17.2) 48 (17.5) 20.29% (26.66% to 6.11%) 0.9b
Patients with rejections over 24-mo study
1 episode 39 (14.6) 41 (14.9)
2 episodes 6 (2.2) 6 (2.2)
3 episodes 1 (0.4) 0 (0.0)
$4 episodes 0 (0.0) 0 (0.0)
Severity of first BPAR episodec
Mild 37 (13.8) 39 (14.2) 0.9d
Moderate 8 (3.0) 10 (3.6)
Severe 1 (0.4) 1 (0.4)
BPAR treated with polyclonal antibodies 9 (3.4) 12 (4.4) 0.6b
Note: Unless otherwise indicated, values are given as number (percentage).
Abbreviations: BPAR, biopsy-proven acute rejection; CI, confidence interval; IR-Tac, immediate-release tacrolimus, twice-daily;
LCPT, extended-release tacrolimus, once daily.
aTwo-sided Newcombe-Wilson score CIs are presented.
bP value from 2-sided Fisher exact test.
cFor BPAR severity, mild is acute T-cell–mediated rejection grade IA or IB; moderate is acute T-cell–mediated rejection grade IIA or
grade IIB; and severe is acute T-cell–mediated rejection grade III using Banff 2007 criteria. BPAR events were based on the central
biopsy reading. Events occurring prior to or on study day 404 or March 18, 2013, whichever is earlier, are included.
dP value from Cochran-Mantel-Haenszel test for general association.
Rostaing et alLaboratory results most commonly reported as an
AE were anemia, hypophosphatemia, leukopenia,
hyperkalemia, increased blood creatinine level, hy-
pokalemia, hypomagnesemia, hyperglycemia, and
vitamin D deﬁciency. Most were mild or moderate in
severity and most were not suspected to be related to
study drug.
Hematology, chemistry, hepatic proﬁle, urinalysis,
vital signs, physical examination, and estimated
glomerular ﬁltration rate results had minimal change
from baseline for both tacrolimus formulations
(Table 4).
Within 24 months after randomization, 24 of
88 (27.3%) and 12 of 74 (16.2%) at-risk patients in
the LCPT and IR-Tac groups, respectively, had
developed NODAT (P 5 0.1). Change from baseline
in hemoglobin A1c level was similar for both treat-
ment groups over the entire study.
DISCUSSION
The results discussed here are from the blinded
24-month follow-up of a phase 3 trial assessing the
efﬁcacy and safety of once-daily LCPT MeltDose
tablets versus IR-Tac capsules in de novo kidney
transplant recipients. Consistent with the 12-month
results,23 this double-blind double-dummy study in
543 recipients showed that once-daily LCPT was
associated with a comparable efﬁcacy and safety
proﬁle as IR-Tac at 24 months postrandomization. The
LCPT group had fewer treatment failures compared to654the IR-Tac group over the duration of the study,
including early posttransplantation (ie, at 3 months),
when there is the greatest risk for rejection; non-
inferiority was demonstrated at 12 months post-
transplantation. Lower LCPT doses were able to
achieve similar trough levels compared to IR-Tac.
Post hoc subgroup analyses showed that the LCPT
group had fewer treatment failures among black re-
cipients, older recipients, and females; each of these
populations has been found to have higher risk for
acute rejection, transplant loss, and/or death.24-28
Lower tacrolimus bioavailability has been observed
in females29,30 and African American kidney trans-
plant recipients, largely due to variations in CYP3A5
gene expression31 and polymorphism preponderance
(CYP3A5*1 allele).32,33 The improved bioavailability
of LCPT may translate into improved clinical out-
comes. Although older recipients generally have less
acute rejection owing to immunosenescence,34,35 early
rejection episodes may be particularly detrimental to
long-term clinical outcomes in older recipients.26,36 It
has also been hypothesized that elderly transplant re-
cipients are likely to have a greater degree of vari-
ability in tacrolimus pharmacokinetics compared with
younger recipients.37 Thus, it is reasonable to hy-
pothesize that LCPTmay be a particularly good option
in older receipts due to improved pharmacokinetics
and efﬁcacy against rejection. The trends observed are
consistent with a post hoc analysis performed on
pooled 12-month data from de novo and stable kidneyAm J Kidney Dis. 2016;67(4):648-659
-60% -40% -20% 0% 20% 40% 60%
In Favor of LCPT In Favor of Twice-daily Tacrolimus
Age <65 yrs. -2.51% (-10.13%, 5.12%), p=0.539 
Age ≥65 yrs. -25.89% (-45.11%, 0.36%), p=0.067 
Black -23.33% (-52.44%, 14.86%), p=0.414
Non-black -2.90% (-10.25%, 4.49%), p=0.474 
Female -11.70% (-23.67%, 0.70%), p=0.0915
Male -0.13% (-9.12%, 8.91%), p>0.999 
All subjects -4.14% (-11.38%, 3.17%), p=0.278 
Figure 5. Forest plot of difference (95% confidence interval) in treatment failure for extended-release tacrolimus, once daily (LCPT)
versus twice-daily tacrolimus by patient subgroups and overall.
LCPT Versus Immediate-Release Tacrolimustransplant recipients, where signiﬁcant differences in
treatment failure were found in both elderly and black
patients for LCPT versus IR-Tac.38
The incidence of treatment-emergent AEs was
similar between both tacrolimus formulations. Kidney
function was similar between the 2 groups throughout
the 24-month study period, as were incidences of
malignancy, infections, and NODAT.
During this 2-year outpatient therapy period, LCPT
patients required lower doses than the IR-Tac group
and the difference increased continually over time
while trough levels remained similar, indicating the
improved absorption by the MeltDose drug delivery
technology. Absorption (ie, bioavailability) per
milligram was signiﬁcantly greater in the LCPT group
versus the IR-Tac group. This result is consistent with
data from phase 2 studies that demonstrated LCPT is
associated with an increase in bioavailability18,39 and
a phase 3 conversion study in which the required
TDD of LCPT was w20% lower than the pre-
conversion IR-Tac dose, whereas drug trough levels
were stable.22
Currently, LCPT is the only extended-release once-
daily tacrolimus formulation that requires a lower
tacrolimus dose to achieve similar exposure levels and
demonstrates comparable efﬁcacy to IR-Tac capsules.Am J Kidney Dis. 2016;67(4):648-659There are conﬂicting data for the importance of
tacrolimus peak concentrations. Although peak con-
centrations are important for cyclosporine-treated pa-
tients,40,41 Undre et al42 reported no association
between peak concentration and rejection for
tacrolimus-treated patients. Instead, overall exposure,
as determined by area under the curve, is important for
good rejection prophylaxis. Conversely, it has been
hypothesized that peak calcineurin inhibitor levels
may be associated with prevention of rejection.40,43
However, results from the present study suggest that
this is not the case because LCPT is associated with an
w30% lower peak compared to IR-Tac, and it is the
achievement of early therapeutic tacrolimus exposure
that is likely more important in preventing rejection.
An advantage of LCPT tablets is their once-a-day
dosing. Multiple daily dosing could contribute to
lack of adherence,8-10,44 and posttransplantation drug
regimens are frequently associated with high pill
burden. Transplant recipients often have lack of
treatment adherence45-47; nonadherence is purported
to be a major contributor to transplant failure48 and a
barrier to improving long-term kidney transplantation
outcomes. Once-daily tacrolimus has been shown to
increase adherence.49,50 In this double-dummy trial,
every patient was assigned to twice-daily dosing in655
Table 4. Summary of AEs, Potentially Clinically Significant
Laboratory Values, and Kidney Function
LCPT
(n 5 268)
IR-Tac
(n 5 275)
AEs
No. of AEs 3,842 3,965
No. of AEs suspected related
to study drug
493 543
Patients with $1 AE 263 (98.1) 269 (97.8)
AEs occurring in $20% of
overall patients
Edema peripheral 50 (18.7) 66 (24.0)
Constipation 51 (19.0) 68 (24.7)
Diabetes mellitus 55 (20.5) 42 (15.3)
Tremor 59 (22.0) 51 (18.5)
Hypertension 71 (26.5) 73 (26.5)
Anemia 75 (28.0) 84 (30.5)
Urinary tract infection 81 (30.2) 80 (29.1)
Diarrhea 91 (34.0) 102 (37.1)
Malignancies
0-12 mo 4 (1.5) 3 (1.1)
0-24 mo 8 (3.0) 8 (2.9)
Infections
Any opportunistica infection
0-12 mo 92 (34.3) 84 (30.5)
0-24 mo 110 (41.0) 99 (36.0)
Cytomegalovirus infection
0-12 mo 31 (11.6) 25 (9.1)
0-24 mo 33 (12.3) 29 (10.5)
BK virus infection
0-12 mo 24 (9.0) 26 (9.5)
0-24 mo 32 (11.9) 31 (11.3)
No. of SAEs 475 519
Patients with $1 SAE 166 (61.9) 185 (67.3)
SAEs occurring in $5% of
overall patients
Urinary tract infection 9.7% 8.0%
Kidney transplant rejection 8.6% 12.0%
Complications of
transplanted kidneyb
3.0% 6.5%
Kidney functionc
eGFR, mL/min/1.73 m2
Baseline 53.9 6 1.27 54.4 6 1.30
Month 24 60.0 6 1.40 60.6 6 1.46
Change from baseline 4.16 1.18 5.16 1.13
Creatinine, mg/dL
Baseline 5.59 6 0.178 5.67 6 0.168
Month 24 1.46 6 0.06 1.49 6 0.07
Change from baseline 23.84 6 0.19 24.056 0.19
Lipids
HDL cholesterol, mg/dL
Baseline 41.7 6 0.82 40.1 6 0.80
Month 24 56.8 6 1.27 53.9 6 1.20
Change from baseline 13.7 6 1.15 14.4 6 1.04
LDL cholesterol, mg/dL
Baseline 86.7 6 2.28 85.1 6 2.11
Month 24 102.4 6 2.01 103.36 2.12
Change from baseline 15.8 6 3.09 17.3 6 2.67
Total cholesterol, mg/dL
Baseline 151.2 6 2.71 148.96 2.37
Month 24 185.7 6 2.66 186.06 2.74
Change from baseline 34.0 6 3.70 36.6 6 3.11
Table 4 (Cont’d). Summary of AEs, Potentially Clinically
Significant Laboratory Values, and Kidney Function
LCPT
(n 5 268)
IR-Tac
(n 5 275)
Triglycerides, mg/dL
Baseline 98.8 6 3.55 102.76 4.39
Month 24 152.66 6.69 167.56 6.83
Change from baseline 57.2 6 6.54 65.1 6 7.06
Note: Unless otherwise indicated, values are given as number
(percentage) or mean 6 standard error. Conversion factors for
units: cholesterol in mg/dL to mmol/L, 30.02586; creatinine in
mg/dL to mmol/L, 388.4; triglycerides in mg/dL to mmol/
L, 30.01129.
Abbreviations: AE, adverse event; eGFR, estimated glo-
merular filtration rate; HDL, high-density lipoprotein; IR-Tac,
immediate-release tacrolimus, twice-daily; LCPT, extended-release
tacrolimus, once daily; LDL, low-density lipoprotein; SAE, serious
adverse event.
aThe opportunistic designation was assigned by the physician.
bMostly delayed transplant function.
cCalculated as month-24 value – baseline value for each
patient.
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Rostaing et alorder to not break the blind. Thus, it was beyond the
scope of this trial to examine whether adherence is
increased for LCPT versus IR-Tac twice daily.
As for all clinical trials, these results and their
generalizability are limited by the patients in a trial
having to meet eligibility criteria to participate and
might not necessarily be representative of the overall
population of de novo kidney transplant recipients. In
addition, trial participants are in a highly controlled
environment and patient behavior (ie, dose adherence
and return for clinical follow-up) and that of the
treating clinicians might differ outside of the trial
conditions, thus inﬂuencing clinical outcomes.
Strengths of this trial include it being double blind
with a titratable drug and blinded for 2 years.
The MeltDose technology with its improved
bioavailability, along with extended drug release, has
resulted in a novel once-daily dosing version of
tacrolimus. Results in this report conﬁrm the beneﬁt
of a lower dose to achieve target trough levels. This
trial offers evidence that LCPT demonstrates com-
parable efﬁcacy to currently available tacrolimus in de
novo kidney transplantation.
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